MMAPPP Act of 2020
Latest action · Aug 5, 2020 Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedAug 5, 2020
- Passed SenateNot reached
- Passed HouseNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Make Medications Affordable by Preventing Pandemic Price gouging Act of 2020 or the MMAPPP Act of 2020
This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.
With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.
The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.
If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.
Cosponsors 6
Members who signed on, in the order they did. Signatures ran from Aug 5, 2020 to Dec 11, 2020; 4 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-OR | Jeff Merkley | Original | Aug 5, 2020 |
| D-CA | Kamala D. Harris | Original | Aug 5, 2020 |
| D-NY | Kirsten E. Gillibrand | Original | Aug 5, 2020 |
| D-WI | Tammy Baldwin | Original | Aug 5, 2020 |
| D-NJ | Cory A. Booker | Aug 6, 2020 | |
| D-CT | Christopher Murphy | Dec 11, 2020 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| Senate | Health, Education, Labor, and Pensions Committee | Referred Aug 5, 2020 |
Actions 2
Everything that happened, newest first.
- Aug 5, 2020Introduced in Senate
- Aug 5, 2020Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
CRS reports 1
Congressional Research Service work that CRS links to this bill or the law it became, newest first.
Cite it 1
Products on other subjects that cite it, usually among other measures.
| Product | Title | Kind | Published |
|---|---|---|---|
| R46741 | Drug Pricing and Intellectual Property: The Legislative Landscape for the 117th Congress | Report | Mar 31, 2021 |
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| HR 7296 | MMAPPP Act of 2020 | Related bill | Jun 22, 2020 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- A bill to require any COVID-19 drug developed in whole or in part with Federal support to be affordable and accessible by prohibiting monopolies and price gouging, and for other purposes.
- Short Title(s) as Introduced
- MMAPPP Act of 2020
- Make Medications Affordable by Preventing Pandemic Price-gouging Act of 2020
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Business records
- Cardiovascular and respiratory health
- Civil actions and liability
- Corporate finance and management
- Drug safety, medical device, and laboratory regulation
- Emergency medical services and trauma care
- Government information and archives
- Health
- Health programs administration and funding
- Health promotion and preventive care
- Immunology and vaccination
- Infectious and parasitic diseases
- Inflation and prices
- Intellectual property
- Licensing and registrations
- Manufacturing
- Medical research
- Medical tests and diagnostic methods
- Performance measurement
- Prescription drugs
- Research administration and funding
- Research and development
- User charges and fees
- Wages and earnings
Text 1
Each version as it was printed, newest first.
- Aug 5, 2020Introduced in Senate
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.
